JP2021519589A5 - - Google Patents
Info
- Publication number
- JP2021519589A5 JP2021519589A5 JP2020552838A JP2020552838A JP2021519589A5 JP 2021519589 A5 JP2021519589 A5 JP 2021519589A5 JP 2020552838 A JP2020552838 A JP 2020552838A JP 2020552838 A JP2020552838 A JP 2020552838A JP 2021519589 A5 JP2021519589 A5 JP 2021519589A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- cdr2
- sequences shown
- cdr3 sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649854P | 2018-03-29 | 2018-03-29 | |
| US62/649,854 | 2018-03-29 | ||
| PCT/US2019/024794 WO2019191563A1 (en) | 2018-03-29 | 2019-03-29 | Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519589A JP2021519589A (ja) | 2021-08-12 |
| JP2021519589A5 true JP2021519589A5 (https=) | 2022-03-29 |
Family
ID=68058546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552838A Pending JP2021519589A (ja) | 2018-03-29 | 2019-03-29 | インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210079087A1 (https=) |
| EP (1) | EP3773717A4 (https=) |
| JP (1) | JP2021519589A (https=) |
| CN (1) | CN112203685A (https=) |
| WO (1) | WO2019191563A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE402192T1 (de) * | 2000-03-03 | 2008-08-15 | Kyowa Hakko Kogyo Kk | Anti-ccr4 antikörper und fragmente davon |
| AU2003239544A1 (en) * | 2002-05-24 | 2003-12-12 | Tularik Inc. | Amplification and overexpression of oncogenes |
| DE10256900A1 (de) * | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US7790862B2 (en) * | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| EP2046835B1 (en) * | 2006-08-11 | 2011-10-26 | Schering Corporation | Antibodies to il-17a |
| EP2493506B1 (en) * | 2009-10-30 | 2019-04-10 | Janssen Biotech, Inc. | Il-17a antagonists |
| LT2953969T (lt) * | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| EP2970446A1 (en) * | 2013-03-15 | 2016-01-20 | Amgen Research (Munich) GmbH | Antibody constructs for influenza m2 and cd3 |
-
2019
- 2019-03-29 WO PCT/US2019/024794 patent/WO2019191563A1/en not_active Ceased
- 2019-03-29 JP JP2020552838A patent/JP2021519589A/ja active Pending
- 2019-03-29 EP EP19778102.4A patent/EP3773717A4/en not_active Withdrawn
- 2019-03-29 US US17/046,220 patent/US20210079087A1/en not_active Abandoned
- 2019-03-29 CN CN201980036330.7A patent/CN112203685A/zh active Pending